Strides Pharma Science reported its highest ever quarterly EBITDA of ₹2,359m in Q3FY26. Revenue grew by 3.6% YoY to ₹11,946m. EBITDA margin increased to 19.8%, a 160bps YoY increase. Operational PAT grew by 38.6% YoY to ₹1,282m, with Operational EPS at ₹13.9.
Q3FY26 Performance Highlights
- Revenue at ₹11,946m, grew 3.6% YoY
- Absolute gross margin at ₹7,317m, grew 8.6% YoY
- Gross margin improved to 61.2%, up 280bps YoY
- EBITDA grew 12.2% YoY to ₹2,359m, EBITDA margin at 19.8%, grew 160bps YoY
- Ex-US Market Revenue at $64m, reported a strong growth of 20% YoY
- Operational PAT at ₹1,282m, Grew 38.6% YoY
- Operational EPS at ₹13.9
- Reported PAT at ₹2,081m
Financial Performance
The company announced consolidated financial results for Q3FY26 and nine months (9MFY26) ended December 31, 2025. Key financial figures include:
| Particulars | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ | 9MFY26 | 9MFY25 | YoY |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11,946 | 11,537 | 3.6% | 12,208 | -2.1% | 35,352 | 33,749 | 4.7% |
| Gross Margin | 7,317 | 6,735 | 8.6% | 7,056 | 3.7% | 21,127 | 18,939 | 11.6% |
| Gross Margin % | 61.2% | 58.4% | 280 bps | 57.8% | 340 bps | 59.8% | 56.1% | 370 bps |
| EBITDA | 2,359 | 2,103 | 12.2% | 2,316 | 1.9% | 6,856 | 5,849 | 17.2% |
| EBITDA % | 19.8% | 18.2% | 160 bps | 19.0% | 80 bps | 19.4% | 17.3% | 210 bps |
| Operational PAT | 1,282 | 925 | 38.6% | 1,403 | -8.6% | 3,824 | 2,317 | 65.0% |
| Operational EPS (*) | 13.9 | 10.0 | 38.4% | 15.2 | -8.6% | 41.5 | 25.2 | 64.7% |
Management Commentary
Badree Komandur, MD & Group CEO, stated that Strides continues to deliver strong performance in Q3FY26, driven by the Other Regulated Markets and Growth Markets. The company’s focus on profitability resulted in gross margin expansion and EBITDA margin increase. The performance demonstrates consistent execution and investment in sustainable, long-term growth. He also welcomed Peter Hardwick as the CEO of the North America business.
Source: BSE
